Medtronic Reveals Plans For Next-Generation ‘Drug-Filled’ Stent
This article was originally published in The Gray Sheet
Executive Summary
The firm characterizes the early-stage technology as its answer to Abbott’s bioabsorbable vascular scaffold and Boston Scientific’s bioabsorbable polymer coronary stents.